Oncotelic Financial Statements From 2010 to 2026
| OTLC Stock | USD 0.08 0 2.75% |
Check Oncotelic Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Oncotelic Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Oncotelic financial statements analysis is a perfect complement when working with Oncotelic Therapeutics Valuation or Volatility modules.
Oncotelic |
Oncotelic Therapeutics OTC Stock Return On Equity Analysis
Oncotelic Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Oncotelic Therapeutics Return On Equity | 0.5 |
Most of Oncotelic Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncotelic Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Oncotelic Therapeutics has a Return On Equity of 0.4967. This is 102.07% lower than that of the Healthcare sector and 101.36% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably lower than that of the firm.
Oncotelic Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Oncotelic Therapeutics's current stock value. Our valuation model uses many indicators to compare Oncotelic Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oncotelic Therapeutics competition to find correlations between indicators driving Oncotelic Therapeutics's intrinsic value. More Info.Oncotelic Therapeutics is considered to be number one stock in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Oncotelic Therapeutics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Oncotelic Therapeutics' OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.About Oncotelic Therapeutics Financial Statements
Oncotelic Therapeutics stakeholders use historical fundamental indicators, such as Oncotelic Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Oncotelic Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Oncotelic Therapeutics' assets and liabilities are reflected in the revenues and expenses on Oncotelic Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Oncotelic Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes and CA4P for the treatment of advanced metastatic melanoma. Oncotelic Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 16 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| JBL | Jabil Circuit | |
| MRK | Merck Company | |
| AMGN | Amgen Inc |
Other Information on Investing in Oncotelic OTC Stock
Oncotelic Therapeutics financial ratios help investors to determine whether Oncotelic OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oncotelic with respect to the benefits of owning Oncotelic Therapeutics security.